Orchestra BioMed (OBIO) Stock Price, News & Analysis

Company Overview

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Key Stats

• Today's Range: $2.49 to $2.62
• 50-Day Range: $2.43 to $3.40
• 52-Week Range: $2.37 to $7.04
• Volume: 127,063 shs
• Average Volume: 295,941 shs
• Market Capitalization: $100.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Buy

Orchestra BioMed Stock Analysis - MarketRank™

Orchestra BioMed scored higher than 62% of companies evaluated by MarketBeat, and ranked 375th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Orchestra BioMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Orchestra BioMed has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Orchestra BioMed are expected to decrease in the coming year, from ($1.66) to ($1.95) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Orchestra BioMed is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Orchestra BioMed is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Orchestra BioMed has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.51% of the float of Orchestra BioMed has been sold short.

Short Interest Ratio / Days to Cover

Orchestra BioMed has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Orchestra BioMed has recently decreased by 9.34%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Orchestra BioMed does not currently pay a dividend.

Dividend Growth

Orchestra BioMed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.51% of the float of Orchestra BioMed has been sold short.

Short Interest Ratio / Days to Cover

Orchestra BioMed has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Orchestra BioMed has recently decreased by 9.34%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: -0.01

News Sentiment

Orchestra BioMed has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Orchestra BioMed this week, compared to 2 articles on an average week.

Search Interest

6 people have searched for OBIO on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Orchestra BioMed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Orchestra BioMed insiders have bought 572.13% more of their company's stock than they have sold. Specifically, they have bought $55,000.00 in company stock and sold $8,183.00 in company stock.

Percentage Held by Insiders

Only 8.10% of the stock of Orchestra BioMed is held by insiders.

Percentage Held by Institutions

53.20% of the stock of Orchestra BioMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OBIO Stock Analysis - Frequently Asked Questions

How have OBIO shares performed this year?

Orchestra BioMed's stock was trading at $4.00 at the beginning of the year. Since then, OBIO shares have decreased by 35.0% and is now trading at $2.60.

How were Orchestra BioMed's earnings last quarter?

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) announced its earnings results on Tuesday, August, 12th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.01. The firm earned $0.84 million during the quarter, compared to analysts' expectations of $0.78 million. Orchestra BioMed had a negative trailing twelve-month return on equity of 289.42% and a negative net margin of 2,367.49%.

Who are Orchestra BioMed's major shareholders?

Orchestra BioMed's top institutional shareholders include Geode Capital Management LLC (0.78%), Knott David M Jr (0.26%), IFP Advisors Inc (0.22%) and Marshall Wace LLP (0.13%). Insiders that own company stock include Darren Sherman, David P Hochman, William Reed Little and Eric S Fain.
View institutional ownership trends.

How do I buy shares of Orchestra BioMed?

Shares of OBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Orchestra BioMed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Orchestra BioMed investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/25/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:OBIO
• CIK: 1814114
• Web: orchestrabiomed.com
• Phone: 646-597-6980
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Orchestra BioMed: $14.00
• High Price Target: $20.00
• Low Price Target: $12.00
• Potential Upside/Downside: +450.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.02 million
• Net Margins: -2,367.49%
• Pretax Margin: -2,367.49%
• Return on Equity: -289.42%
• Return on Assets: -110.04%

Debt

• Debt-to-Equity Ratio: 48.76
• Current Ratio: 2.10
• Quick Ratio: 2.09

Sales & Book Value

• Annual Sales: $2.64 million
• Price / Sales: 37.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.87 per share
• Price / Book: 2.92

Miscellaneous

• Outstanding Shares: 38,640,000
• Free Float: 35,514,000
• Market Cap: $98.30 million
• Optionable: Not Optionable
• Beta: 0.62